Craig H Mermel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2785632/publications.pdf

Version: 2024-02-01

59 papers

45,348 citations

45 h-index 58 g-index

60 all docs 60 does citations

60 times ranked

60557 citing authors

#	Article	IF	CITATIONS
1	Artificial intelligence for diagnosis and Gleason grading of prostate cancer: the PANDA challenge. Nature Medicine, 2022, 28, 154-163.	30.7	143
2	Current and future applications of artificial intelligence in pathology: a clinical perspective. Journal of Clinical Pathology, 2021, 74, 409-414.	2.0	57
3	Closing the translation gap: Al applications in digital pathology. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1875, 188452.	7.4	31
4	Interpretable survival prediction for colorectal cancer using deep learning. Npj Digital Medicine, 2021, 4, 71.	10.9	95
5	Predicting prostate cancer specific-mortality with artificial intelligence-based Gleason grading. Communications Medicine, $2021,1,.$	4.2	24
6	Determining breast cancer biomarker status and associated morphological features using deep learning. Communications Medicine, 2021, 1, .	4.2	53
7	Comparative analysis of machine learning approaches to classify tumor mutation burden in lung adenocarcinoma using histopathology images. Scientific Reports, 2021, 11, 16605.	3.3	21
8	Evaluation of artificial intelligence on a reference standard based on subjective interpretation. The Lancet Digital Health, 2021, 3, e693-e695.	12.3	21
9	Artificial intelligence in digital breast pathology: Techniques and applications. Breast, 2020, 49, 267-273.	2.2	117
10	Evaluation of the Use of Combined Artificial Intelligence and Pathologist Assessment to Review and Grade Prostate Biopsies. JAMA Network Open, 2020, 3, e2023267.	5.9	56
11	Development and Validation of a Deep Learning Algorithm for Gleason Grading of Prostate Cancer From Biopsy Specimens. JAMA Oncology, 2020, 6, 1372.	7.1	119
12	Deep learning-based survival prediction for multiple cancer types using histopathology images. PLoS ONE, 2020, 15, e0233678.	2.5	143
13	An augmented reality microscope with real-time artificial intelligence integration for cancer diagnosis. Nature Medicine, 2019, 25, 1453-1457.	30.7	179
14	Reply: â€~The importance of study design in the application of artificial intelligence methods in medicine'. Npj Digital Medicine, 2019, 2, 100.	10.9	2
15	Similar image search for histopathology: SMILY. Npj Digital Medicine, 2019, 2, 56.	10.9	91
16	Development and validation of a deep learning algorithm for improving Gleason scoring of prostate cancer. Npj Digital Medicine, 2019, 2, 48.	10.9	244
17	Whole-Slide Image Focus Quality: Automatic Assessment and Impact on Al Cancer Detection. Journal of Pathology Informatics, 2019, 10, 39.	1.7	58
18	Identification of and Molecular Basis for SIRT6 Loss-of-Function Point Mutations in Cancer. Cell Reports, 2015, 13, 479-488.	6.4	64

#	Article	IF	Citations
19	RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. Nature Communications, 2015, 6, 6377.	12.8	498
20	Clinical Acquired Resistance to RAF Inhibitor Combinations in <i>BRAF</i> -Mutant Colorectal Cancer through MAPK Pathway Alterations. Cancer Discovery, 2015, 5, 358-367.	9.4	265
21	Computational Pathology: An Emerging Definition. Archives of Pathology and Laboratory Medicine, 2014, 138, 1133-1138.	2.5	78
22	Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes. New England Journal of Medicine, 2014, 371, 2488-2498.	27.0	3,474
23	The 2013 symposium on pathology data integration and clinical decision support and the current state of field. Journal of Pathology Informatics, 2014, 5, 2.	1.7	14
24	Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood, 2014, 123, e123-e133.	1.4	337
25	Discovery and saturation analysis of cancer genes across 21 tumour types. Nature, 2014, 505, 495-501.	27.8	2,586
26	Clonal Hematopoiesis with Somatic Mutations Is a Common, Age-Related Condition Associated with Adverse Outcomes. Blood, 2014, 124, 840-840.	1.4	1
27	Pan-cancer patterns of somatic copy number alteration. Nature Genetics, 2013, 45, 1134-1140.	21.4	1,616
28	Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature, 2013, 499, 214-218.	27.8	4,761
29	Systematic Interrogation of 3q26 Identifies <i>TLOC1</i> and <i>SKIL</i> as Cancer Drivers. Cancer Discovery, 2013, 3, 1044-1057.	9.4	71
30	Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. Journal of Clinical Investigation, 2013, 123, 517-25.	8.2	462
31	Abstract SY25-03: Haploinsufficiency in cancer: When half simply isn't good enough, 2013,,.		0
32	Integrative Analysis Reveals an Outcome-Associated and Targetable Pattern of p53 and Cell Cycle Deregulation in Diffuse Large B Cell Lymphoma. Cancer Cell, 2012, 22, 359-372.	16.8	179
33	Recurrent Hemizygous Deletions in Cancers May Optimize Proliferative Potential. Science, 2012, 337, 104-109.	12.6	172
34	Detection of Preanalytic Laboratory Testing Errors Using a Statistically Guided Protocol. American Journal of Clinical Pathology, 2012, 138, 406-413.	0.7	31
35	Developing Algorithms to Discover Novel Cancer Genes: A look at the challenges and approaches. IEEE Signal Processing Magazine, 2012, 29, 89-97.	5.6	7
36	A Structural Basis for p53-Deficiency, Deregulated Cell Cycle and Unfavorable Outcome in Diffuse Large B-Cell Lymphoma. Blood, 2012, 120, 1534-1534.	1.4	0

#	Article	IF	CITATIONS
37	Integrated genomic analyses of ovarian carcinoma. Nature, 2011, 474, 609-615.	27.8	6,541
38	GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biology, 2011, 12, R41.	8.8	2,546
39	The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset. Nature, 2011, 471, 513-517.	27.8	506
40	How surgical residents use social media. Surgery, 2011, 150, 5-6.	1.9	11
41	Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 12372-12377.	7.1	383
42	Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung Cancer. PLoS ONE, 2011, 6, e20351.	2.5	338
43	The landscape of somatic copy-number alteration across human cancers. Nature, 2010, 463, 899-905.	27.8	3,331
44	Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nature Genetics, 2010, 42, 715-721.	21.4	642
45	ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor. Modern Pathology, 2010, 23, 1061-1067.	5.5	114
46	Integrated Genome-Wide DNA Copy Number and Expression Analysis Identifies Distinct Mechanisms of Primary Chemoresistance in Ovarian Carcinomas. Clinical Cancer Research, 2009, 15, 1417-1427.	7.0	266
47	Amplification of chromosomal segment 4q12 in non-small cell lung cancer. Cancer Biology and Therapy, 2009, 8, 2042-2050.	3.4	78
48	<i>PTEN</i> Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR. Cancer Research, 2009, 69, 3256-3261.	0.9	480
49	Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature, 2009, 462, 108-112.	27.8	2,707
50	Lin28 promotes transformation and is associated with advanced human malignancies. Nature Genetics, 2009, 41, 843-848.	21.4	742
51	SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nature Genetics, 2009, 41, 1238-1242.	21.4	862
52	Predicting drug susceptibility of non–small cell lung cancers based on genetic lesions. Journal of Clinical Investigation, 2009, 119, 1727-1740.	8.2	230
53	microRNA Expression during Trophectoderm Specification. PLoS ONE, 2009, 4, e6143.	2.5	71
54	CDK8 is a colorectal cancer oncogene that regulates \hat{l}^2 -catenin activity. Nature, 2008, 455, 547-551.	27.8	594

#	Article	IF	CITATIONS
55	Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature, 2008, 455, 1061-1068.	27.8	6,879
56	<i>EML4-ALK</i> Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer. Clinical Cancer Research, 2008, 14, 4275-4283.	7.0	916
57	Highly parallel identification of essential genes in cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 20380-20385.	7.1	499
58	Src family kinases are important negative regulators of G-CSF-dependent granulopoiesis. Blood, 2006, 108, 2562-2568.	1.4	44
59	ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 3788-3793.	7.1	472